Futura Medical PLC Eroxon Awarded "New Product of the Year" by Boots
02 November 2023 - 4:34PM
RNS Non-Regulatory
TIDMFUM
Futura Medical PLC
02 November 2023
2 November 2023
Futura Medical plc
("Futura" or the "Company")
Eroxon Awarded "New Product of the Year, Healthcare" by
Boots
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the
pharmaceutical company developing innovative sexual health
products, announces that Eroxon (R) has won the "New Product of the
Year, Healthcare" category at the Boots Supplier Awards 2023,
following its UK launch earlier this year. The award is further
recognition for Futura's breakthrough treatment for erectile
dysfunction ("ED") as it provides an alternative treatment option
for the 4.3 million men in the UK experiencing symptoms*.
James Barder, Chief Executive Officer of Futura said : "Winning
the "New Product of the Year, Healthcare" award at this year's
Boots Supplier Awards is great recognition for Eroxon (R) by one of
Britain's most trusted brands. Eroxon(R) is a potential game
changer for the 4.3 million men who suffer from ED in the UK and we
are delighted to see it getting the recognition it deserves."
*Figures based on men reporting occasional and frequent
difficulty getting or maintaining an erection, ref Kantar TNS
Omnibus Survey Dec 2010 in a survey of 1,033 men. Stats are UK
unless stated otherwise.
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
For media enquiries please contact:
Optimum Strategic Communications
Nick Bastin / Jonathan Edwards/ Zoe Bolt / Elena Bates
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Development and
commercialisation strategies are designed to maximise product
differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a novel
treatment for erectile dysfunction (ED) through a unique
evaporative mode of action. Futura has conducted two Phase 3
studies using MED3000 in ED; FM57 study which enabled Futura to be
granted a CE Mark in 2021 and FM71 which enabled Futura to be
granted US marketing authorisation. Both studies demonstrated that
MED3000 presents an effective clinically proven treatment for ED
with a rapid speed of onset and a favourable benefit versus risk
profile ideally suited for an 'Over the Counter'
classification.
Eroxon(R) is FDA approved in the US, CE marked in Europe and
UKCA marked in the UK as a clinically proven topical treatment for
adult men with erectile dysfunction under the brand Eroxon(R) with
a key claim of "Helps you get an erection within 10 minutes".
Eroxon(R) is the agreed brand name in certain regions such as the
EU whereas MED3000 continues to be the internal code name used by
the Company and also in reference to countries where regulatory
approval or commercial distribution agreements have not yet been
achieved. www.eroxon.com
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange. www.futuramedical.com
.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFZMGMKZZGFZM
(END) Dow Jones Newswires
November 02, 2023 11:34 ET (15:34 GMT)
Futura Medical (LSE:FUM)
Historical Stock Chart
Von Okt 2024 bis Okt 2024
Futura Medical (LSE:FUM)
Historical Stock Chart
Von Okt 2023 bis Okt 2024